The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions

Natale Belluardo, Giuseppa Mudò, Giuseppa Caniglia, Qingzhang Cheng, Mariann Blum, Kjell Fuxe

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

THE present experiments were designed to extend previous work showing that acute intermittent (-)nicotine treatment upregulates the level of fibroblast growth factor-2 (FGF2) mRNA in several rat brain regions, by the use of the nicotinic acetylcholine receptor (nAChR) agonist ABT-594 with preferential selectivity for the α4β2 nAChR subtype. ABT594 treatment led to a well-defined temporal and regional upregulation of FGF-2 mRNA. A double labelling analysis showed that the up-regulation of FGF-2 mRNA involves both neuronal and non-neuronal cells. The effects of ABT-594 on FGF-2 expression were antagonized by the preferential α4β2 antagonist dihydro-βerythroidine (DHβE), but not by α7 antagonist metyllycaconitine (MLA). In conclusion, FGF-2 mRNA levels can be increased in several brain regions upon α4β2 nAChR activation, suggesting a therapeutic significance in neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)3909-3913
Number of pages5
JournalNeuroReport
Volume10
Issue number18
DOIs
StatePublished - Dec 16 1999
Externally publishedYes

Keywords

  • ABT-594
  • Brain
  • FGF-2
  • NAChR
  • α4β2 subtype

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions'. Together they form a unique fingerprint.

Cite this